Table 2 Relationship between treatment type and patient characteristics (n = 161)
|  | Chemotherapy (n = 67) | Radiotherapy (n = 29) | Combined chemoradiotherapy (n = 58) | No treatment (n = 7) | p-valuea |
|---|---|---|---|---|---|
Age | Â | Â | Â | Â | 0.046 |
  ≤ 60 years | 42 (41%) | 14 (14%) | 43 (42%) | 4 (3%) |  |
  > 60 years | 25 (43%) | 15 (26%) | 15 (26%) | 3 (5%) |  |
FIGO stage | Â | Â | Â | Â | 0.389 |
 IIIA or IIIB | 30 (49%) | 8 (13%) | 20 (33%) | 3 (5%) |  |
 IIIC | 37 (37%) | 21 (21%) | 38 (38%) | 4 (4%) |  |
Histology | Â | Â | Â | Â | 0.059 |
 Endometrioid | 56 (41%) | 28 (20%) | 49 (36%) | 4 (3%) |  |
 Non-endometrioid | 11 (46%) | 1 (4%) | 9 (38%) | 3 (12%) |  |
Tumor grade | Â | Â | Â | Â | 0.185 |
 1–2 | 46 (42%) | 24 (22%) | 35 (32%) | 4 (4%) |  |
 3 | 21 (40%) | 5 (10%) | 23 (44%) | 3 (6%) |  |
Lymphovascular space invasion | Â | Â | Â | Â | 0.225 |
 Nil | 22 (52%) | 4 (10%) | 15 (36%) | 1 (2%) |  |
 Present | 45 (38%) | 25 (21%) | 43 (36%) | 6 (5%) |  |
Peritoneal cytology | Â | Â | Â | Â | 0.111 |
 Negative | 45 (367%) | 23 (19%) | 47 (39%) | 7 (6%) |  |
 Positive | 22 (576%) | 6 (15%) | 11 (28%) | 0 (0%) |  |
≥2 positive LN |  |  |  |  | 0.669 |
 Nil | 38 (44%) | 14 (16%) | 30 (34%) | 5 (6%) |  |
 Present | 29 (39%) | 15 (20%) | 28 (38%) | 2 (3%) |  |